Literature DB >> 20051275

Changes in trabecular microarchitecture in postmenopausal women on bisphosphonate therapy.

Susan L Greenspan1, Subashan Perera, Robert Recker, Julie M Wagner, Parmatma Greeley, Bryon R Gomberg, Pamela Seaman, Michael Kleerekoper.   

Abstract

PURPOSE: In addition to bone mineral density (BMD), trabecular microstructure contributes to skeletal strength. Our goal was to examine changes in trabecular microstructure in women on therapy.
MATERIALS AND METHODS: We followed 10 postmenopausal women receiving a bisphosphonate, risedronate (35 mg once weekly), over 12 months and examined trabecular microarchitecture with high resolution wrist MR images (hr-MRI). MRI parameters included bone volume/total volume (BV/TV), surface density (representing plates), curve density (representing rods), surface-to-curve ratio and erosion index (depicting deterioration). We assessed BMD of the spine, hip and radius and markers of bone turnover.
RESULTS: Women had been receiving bisphosphonate therapy for 43+/-9 months (mean+/-SD) prior to the first MRI. Indices of hr-MRI demonstrated improvement in surface-to-curve ratio (13.0%) and a decrease in erosion index (12.1%) consistent with less deterioration (both p<0.05). BMD of the spine, hip and radius and markers of bone turnover remained stable. Parameters of hr-MRI were associated with 1/3 distal radius BMD (correlation coefficient 0.71 to 0.86, p<0.05). DISCUSSION: We conclude that hr-MRI of the radius demonstrates improvements in trabecular microstructure not appreciated by conventional BMD and provides additional information on parameters that contribute to structural integrity in patients on antiresorptive therapy. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20051275      PMCID: PMC3889111          DOI: 10.1016/j.bone.2009.12.025

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  21 in total

Review 1.  Role of magnetic resonance for assessing structure and function of trabecular bone.

Authors:  Felix W Wehrli; Punam K Saha; Bryon R Gomberg; Hee Kwon Song; Peter J Snyder; Maria Benito; Alex Wright; Richard Weening
Journal:  Top Magn Reson Imaging       Date:  2002-10

Review 2.  Mechanisms of osteoporosis therapy: a bone strength perspective.

Authors:  Mary L Bouxsein
Journal:  Clin Cornerstone       Date:  2003

3.  Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.

Authors:  S L Greenspan; S Holland; L Maitland-Ramsey; M Poku; A Freeman; W Yuan; U Kher; B Gertz
Journal:  Proc Assoc Am Physicians       Date:  1996-05

4.  Digital topological analysis of in vivo magnetic resonance microimages of trabecular bone reveals structural implications of osteoporosis.

Authors:  F W Wehrli; B R Gomberg; P K Saha; H K Song; S N Hwang; P J Snyder
Journal:  J Bone Miner Res       Date:  2001-08       Impact factor: 6.741

Review 5.  Pathogenesis of bone fragility in women and men.

Authors:  Ego Seeman
Journal:  Lancet       Date:  2002-05-25       Impact factor: 79.321

6.  Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.

Authors:  Marc C Hochberg; Susan Greenspan; Richard D Wasnich; Paul Miller; Desmond E Thompson; Philip D Ross
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

7.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

8.  Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.

Authors:  Babul Borah; Thomas E Dufresne; Paula A Chmielewski; Troy D Johnson; Arkadi Chines; Michael D Manhart
Journal:  Bone       Date:  2004-04       Impact factor: 4.398

9.  Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital.

Authors:  Kuntheavy Ing-Lorenzini; Jules Desmeules; Olivier Plachta; Domizio Suva; Pierre Dayer; Robin Peter
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  Ten years' experience with alendronate for osteoporosis in postmenopausal women.

Authors:  Henry G Bone; David Hosking; Jean-Pierre Devogelaer; Joseph R Tucci; Ronald D Emkey; Richard P Tonino; Jose Adolfo Rodriguez-Portales; Robert W Downs; Jayanti Gupta; Arthur C Santora; Uri A Liberman
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

View more
  15 in total

1.  Fractal dimension evaluation of cone beam computed tomography in patients with bisphosphonate-associated osteonecrosis.

Authors:  S R Torres; C S K Chen; B G Leroux; P P Lee; L G Hollender; M M Schubert
Journal:  Dentomaxillofac Radiol       Date:  2011-12       Impact factor: 2.419

2.  Cortical and trabecular bone structure analysis at the distal radius-prediction of biomechanical strength by DXA and MRI.

Authors:  Thomas Baum; Melanie Kutscher; Dirk Müller; Christoph Räth; Felix Eckstein; Eva-Maria Lochmüller; Ernst J Rummeny; Thomas M Link; Jan S Bauer
Journal:  J Bone Miner Metab       Date:  2012-11-22       Impact factor: 2.626

3.  Microstructure of the Distal Radius and Its Relevance to Distal Radius Fractures.

Authors:  Gregory Ian Bain; Simon Bruce Murdoch MacLean; Tom McNaughton; Ruth Williams
Journal:  J Wrist Surg       Date:  2017-05-10

4.  Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy.

Authors:  Susan L Greenspan; Julie Wagner; Joel B Nelson; Subashan Perera; Cynthia Britton; Neil M Resnick
Journal:  J Bone Miner Res       Date:  2013-02       Impact factor: 6.741

5.  Mandibular inferior cortical bone thickness on panoramic radiographs in patients using bisphosphonates.

Authors:  Sandra R Torres; Curtis S K Chen; Brian G Leroux; Peggy P Lee; Lars G Hollender; Michelle Lloid; Shane Patrick Drew; Mark M Schubert
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2015-02-14

6.  Reduced bone mineral density is not associated with significantly reduced bone quality in men and women practicing long-term calorie restriction with adequate nutrition.

Authors:  Dennis T Villareal; John J Kotyk; Reina C Armamento-Villareal; Venkata Kenguva; Pamela Seaman; Allon Shahar; Michael J Wald; Michael Kleerekoper; Luigi Fontana
Journal:  Aging Cell       Date:  2010-11-15       Impact factor: 9.304

Review 7.  MRI assessment of bone structure and microarchitecture.

Authors:  Gregory Chang; Sean Boone; Dimitri Martel; Chamith S Rajapakse; Robert S Hallyburton; Mitch Valko; Stephen Honig; Ravinder R Regatte
Journal:  J Magn Reson Imaging       Date:  2017-02-06       Impact factor: 4.813

8.  Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid.

Authors:  Edmund K Li; Tracy Y Zhu; Vivian Y Hung; Anthony W Kwok; Vivian W Lee; Kenneth K Lee; James F Griffith; Martin Li; Kong Chiu Wong; Ping Chung Leung; Ling Qin; Lai Shan Tam
Journal:  Arthritis Res Ther       Date:  2010-10-22       Impact factor: 5.156

9.  Are there any differences in mandibular morphology of patients with bisphosphonate-related osteonecrosis of jaws?: a case-control study.

Authors:  Gozde Ozcan; Ahmet E Sekerci; Zeynep B Gönen
Journal:  Dentomaxillofac Radiol       Date:  2016-05-16       Impact factor: 2.419

10.  Trabecular bone structure analysis of the spine using clinical MDCT: can it predict vertebral bone strength?

Authors:  Thomas Baum; Martin Gräbeldinger; Christoph Räth; Eduardo Grande Garcia; Rainer Burgkart; Janina M Patsch; Ernst J Rummeny; Thomas M Link; Jan S Bauer
Journal:  J Bone Miner Metab       Date:  2013-04-20       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.